AirSculpt Technologies, Inc. (NASDAQ:AIRS) Q2 2024 Earnings Call August 9, 2024 8:30 AM ET
Company Participants
Allison Malkin - Investor Relations
Aaron Rollins - Founder and Executive Chairman
Dennis Dean - Interim Chief Executive Officer and Chief Financial Officer
Conference Call Participants
Korinne Wolfmeyer - Piper Sandler
Josh Raskin - Nephron Research
Operator
Greetings and welcome to the AirSculpt Technologies Second Quarter Fiscal 2024 Earnings Call. [Operator Instructions] I would now like to turn the conference over to your host, Allison Malkin with ICR. Thank you. You may begin.
Allison Malkin
Good morning, everyone. Thank you for joining us to discuss AirSculpt Technologies results for the second quarter of fiscal 2024. Joining me on the call today are the company’s Founder and Executive Chairman, Dr. Aaron Rollins; and Interim Chief Executive Officer and Chief Financial Officer, Dennis Dean.
Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities and our growth. Risks and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning’s press release and the reports we will file with the SEC, all of which can be found on our website at investors.airsculpt.com. We undertake no obligation to revise or update any forward-looking statements or information, except as required by law.
During this call, we will also reference certain non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-Q, which also will be available on our website.
With that, I’ll turn the call over to Dr. Rollins.
Aaron Rollins
Good morning, everyone, and thank you for joining today’s call. Earlier this morning, we announced second quarter results below our expectations amidst challenging demand backdrop. Despite these results, we remain committed to reestablishing our same-store growth trajectory, opening and ramping our de novo centers and improving our operating margins.
To achieve these objectives, the management team’s current focus is on back to basics. For us, that means investing prudently in our performance marketing efforts, providing the best experience for our patients and letting our doctors do what they are expertly trained to do, which is perform best-in-class body contouring procedures using our proprietary AirSculpt technology.